Work

Red ginseng RG-I-enriched pectin inhibits 4T1 tumour growth and improves cisplatin response

Year: 2026
Type: preprint
Abstract: Background and purpose: Red ginseng polysaccharides have antitumour potential, but the contribution of individual pectic domains remains unclear. We investigated the activity of a rhamnogalacturonan-I (RG-I)-enriched fraction in triple-negative breast cancer and the involvement of gut microbiota in its response to cisplatin. Experimental Approach: The fraction was isolated by enzymatic digestion and chromatography and characterised by sugar composition, nuclear magnetic resonance and linkage analysis. 4T1-bearing mice received crude red ginseng polysaccharides, the enriched fraction, cisplatin or the fraction plus cisplatin, alongside tumour controls and corresponding antibiotic-pretreated groups. Tumour growth, histology, 16S rRNA sequencing, RNA-seq, quantitative PCR and Western blot were assessed. Key Results: The 83.0-kDa fraction had a galacturonic acid/rhamnose ratio of 1.06 and abundant arabinose/galactose side-chain features. It inhibited tumour growth more strongly than crude polysaccharides, with the greatest reduction in the RG-I plus cisplatin group. Antibiotic pretreatment attenuated these effects. The fraction increased Lactobacillus, Blautia and Lachnospiraceae-related taxa and reduced opportunistic genera. RNA-seq and quantitative PCR showed inflammatory and metabolic changes, alongside lower Ki-67 and higher TUNEL labelling. Western blot profiles differed between conventional and antibiotic-pretreated combination groups. Conclusions and Implications: RG-I-enriched red ginseng pectin suppresses 4T1 tumour growth and improves cisplatin response alongside gut microbiota and tumour-associated molecular remodelling, supporting its development as a microbiota-oriented adjunct for triple-negative breast cancer.
Language: English
Subfield: Plant Science
Open Access status: green
OpenAlex ID: W7226011857
Cites:
Cited by:
Related to: 10